Skip to main content

Table 1 Demographic and clinical characteristics of 53 patients included in the study submitted to radical prostatectomy to treat prostate cancer

From: miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer

Age (years) Mean

65.4

Min - Max

50 - 79

PSA (ng/ml) Mean

11.0

Min - Max

2.0 – 37.0

<10 n (%)

27 (50.1)

≥10 n (%)

26 (49.9)

Stage

 

pT2 n (%)

22 (42.3)

pT3 n (%)

30 (57.7)

Gleason Score

 

< 7 n (%)

22 (41.5)

≥ 7 n (%)

31 (58.5)